Giovanni Caocci1, Olga Mulas2, Mario Annunziata3, Luigiana Luciano4, Elisabetta Abruzzese5, Massimiliano Bonifacio6, Ester Maria Orlandi7, Francesco Albano8, Sara Galimberti9, Alessandra Iurlo10, Patrizia Pregno11, Nicola Sgherza12, Bruno Martino13, Gianni Binotto14, Fausto Castagnetti15, Antonella Gozzini16, Monica Bocchia17, Claudio Fozza18, Fabio Stagno19, Maria Pina Simula20, Fiorenza De Gregorio4, Malgorzata Monika Trawinska5, Luigi Scaffidi6, Chiara Elena7, Imma Attolico8, Claudia Baratè9, Daniele Cattaneo10, Francesca Pirillo11, Gabriele Gugliotta15, Anna Sicuranza17, Matteo Molica21, Giorgio La Nasa2, Robin Foà21, Massimo Breccia21. 1. Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. Electronic address: giovanni.caocci@unica.it. 2. Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. 3. Hematology Unit, Cardarelli Hospital, Naples, Italy. 4. Hematology Unit "Federico II" University of Naples, Naples, Italy. 5. Hematology Unit, Sant'Eugenio Hospital Tor Vergata University, Rome, Italy. 6. Department of Medicine, Section of Hematology, University of Verona, Verona, Italy. 7. Hematology Unit, "Fondazione IRCCS Policlinico S. Matteo" University Hospital, Pavia, Italy. 8. Haematology and Transplants Unit, University of Bari, Bari, Italy. 9. Department of Clinical and Experimental Medicine, Section of Hematology, University of Pisa, Pisa, Italy. 10. Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy. 11. Hematology Unit, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy. 12. Hematology and Transplant Center, Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy. 13. Hematology Unit, Azienda Ospedaliera "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy. 14. Hematology Unit, University of Padova, Padua, Italy. 15. Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. 16. Hematology Unit, AOU Careggi, University of Florence, Florence, Italy. 17. Hematology Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy. 18. Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy. 19. Hematology Unit, Ferrarotto Hospital, Catania, Italy. 20. Hematology and Transplant Center, Businco Hospital, Cagliari, Italy. 21. Division of Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy.
Abstract
BACKGROUND: Limited information is available regarding the rate of long-term cardiovascular (CV) mortality in chronic myeloid leukaemia (CML) patients treated with second- and third-generation tyrosine kinase inhibitors (2ndG/3rdG TKIs) in the real-life practice. METHODS: We identified 656 consecutive CML patients treated with nilotinib, dasatinib, bosutinib and ponatinib. RESULTS: The 15-year CV-mortality free survival was 93 ± 2.8%. Age ≥65 years (p = 0.005) and a positive history of CV disease (p = 0.04) were significantly associated with a lower CV-mortality free survival. CV disease accounted for 16.5% and 5% of potential years of life lost (PYLL) in male and female patients, respectively. The standard mortality ratio (SMR) following ischemic heart disease (IHD) was 3.9 in males and 3.8 in female patients, meaning an excess of IHD deaths observed, in comparison with the population of control. CONCLUSION: Prevention strategies based on CV risk factors, in particular in those patients with a previous history of CV disease, should be considered.
BACKGROUND: Limited information is available regarding the rate of long-term cardiovascular (CV) mortality in chronic myeloid leukaemia (CML) patients treated with second- and third-generation tyrosine kinase inhibitors (2ndG/3rdG TKIs) in the real-life practice. METHODS: We identified 656 consecutive CML patients treated with nilotinib, dasatinib, bosutinib and ponatinib. RESULTS: The 15-year CV-mortality free survival was 93 ± 2.8%. Age ≥65 years (p = 0.005) and a positive history of CV disease (p = 0.04) were significantly associated with a lower CV-mortality free survival. CV disease accounted for 16.5% and 5% of potential years of life lost (PYLL) in male and female patients, respectively. The standard mortality ratio (SMR) following ischemic heart disease (IHD) was 3.9 in males and 3.8 in female patients, meaning an excess of IHD deaths observed, in comparison with the population of control. CONCLUSION: Prevention strategies based on CV risk factors, in particular in those patients with a previous history of CV disease, should be considered.
Authors: Stephanie M Smith; Himalee S Sabnis; Rebecca Williamson Lewis; Karen E Effinger; John Bergsagel; Briana Patterson; Ann Mertens; Kathleen M Sakamoto; Lidia Schapira; Sharon M Castellino Journal: BMC Cancer Date: 2021-04-29 Impact factor: 4.430